NYSEHealth CareHealth Care TechnologyS&P MidCap 400
$32.51
-0.67 (-2.02%)
Close of Nov 06, 2026 · end-of-day data
DOCS 8-K filings in 2026
Every material Form 8-K Doximity filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Doximity reported fiscal second-quarter revenue of $174.5 million, up 4% from a year earlier, but net income fell to $34.7 million from $62.1 million and adjusted EBITDA declined 12% to $88.9 million. The company also gave fiscal third-quarter and updated full-year fiscal 2027 guidance, which shareholders can compare against these results.
Revenue of $174.5 million versus $168.5 million, up 4% year-over-year
Net income of $34.7 million versus $62.1 million; diluted EPS of $0.18 versus $0.31
Adjusted EBITDA of $88.9 million versus $100.8 million, down 12%; margin 50.9% versus 59.8%
Fiscal 2027 revenue guidance of $678 million to $683 million and adjusted EBITDA of $317 million to $325 million; third-quarter revenue guidance of $195 million to $196 million
Doximity reported fiscal first-quarter 2027 results for the quarter ended June 30, 2026, with revenue up 7% year-over-year but net income and adjusted EBITDA both lower than a year earlier. The company also gave revenue and adjusted EBITDA guidance for its fiscal second quarter and updated its full fiscal 2027 outlook, so shareholders face a mix of growth and declining profit.
Revenue was $156.6 million, up 7% from $145.9 million a year earlier.
Net income was $24.3 million, down from $53.3 million; diluted EPS was $0.13 versus $0.27.
Adjusted EBITDA was $74.8 million, down 6% from $79.8 million; free cash flow was $39.6 million, down 34%.
Guidance: fiscal Q2 revenue of $170 million to $171 million; fiscal 2027 revenue of $671 million to $681 million and adjusted EBITDA of $309 million to $329 million.
Doximity reported fiscal fourth-quarter 2026 revenue of $145.4 million, up 5%, but GAAP net income fell to $19.1 million from $62.5 million and adjusted EBITDA declined 6%. The company also gave fiscal 2027 revenue guidance of $664 million to $676 million and named Matthew Sonefeldt as chief financial officer and Steven L. Zatz, M.D. as president, both effective May 13, 2026.
Q4 revenue $145.4 million vs. $138.3 million; net income $19.1 million vs. $62.5 million; diluted EPS $0.10 vs. $0.31
Q4 adjusted EBITDA $65.8 million vs. $69.7 million; full-year fiscal 2026 revenue $644.9 million, up 13%
Fiscal 2027 guidance: revenue $664 million to $676 million; adjusted EBITDA $323 million to $335 million; fiscal Q1 revenue $151 million to $152 million
Matthew Sonefeldt becomes principal financial officer June 8, 2026; Siddharth Sitaram serves as interim PFO through June 7, 2026
Doximity disclosed that Chief Financial Officer Anna Bryson, who had been on medical leave, resigned on April 13, 2026, and that Chief Accounting Officer Siddharth Sitaram has served as interim principal financial and accounting officer since February 3, 2026. The company also reaffirmed its guidance for the fourth quarter and full fiscal year ending March 31, 2026, given on February 5, 2026, which matters to shareholders because it signals no change to prior expectations despite the leadership transition.
CFO Anna Bryson resigned; the company accepted her resignation on April 13, 2026
Siddharth Sitaram, Chief Accounting Officer, serves as interim principal financial and accounting officer, effective February 3, 2026
Company reaffirmed fourth quarter and full fiscal year 2026 guidance first given February 5, 2026
Company expects to update on the CFO search during its next earnings call
Doximity reported fiscal third-quarter revenue of $185.1 million, up 10% year-over-year, while GAAP net income fell to $61.6 million from $75.2 million. The company updated its full-year fiscal 2026 revenue and adjusted EBITDA guidance and authorized a new $500 million share repurchase program. Chief Financial Officer Anna Bryson is on a temporary medical leave, and Chief Accounting Officer Siddharth Sitaram has been named interim principal financial and accounting officer effective February 3, 2026.
Q3 revenue of $185.1 million, up 10%; GAAP diluted EPS of $0.31 versus $0.37 a year earlier
Adjusted EBITDA of $111.4 million, up 9%; non-GAAP diluted EPS of $0.46 versus $0.45
Fiscal 2026 revenue guidance updated to $642.5 million to $643.5 million; adjusted EBITDA guidance to $355.5 million to $356.5 million
CFO Anna Bryson on temporary medical leave; Siddharth Sitaram appointed interim principal financial officer effective February 3, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Doximity filing is on SEC EDGAR ↗. 8-K briefs of other companies →